BioSpace1h
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
Fierce Biotech1d
Immunocore T-cell engager clears safety hurdle, reduces HIV reservoir in some patients
Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...
The American Journal of Managed Care5d
CROI 2025 Promises Breaking Results, Conversations Around HIV, COVID-19
This year’s Conference on Retroviruses and Opportunistic Infections (CROI) features several sessions discussing prevention ...
Fierce Pharma9d
How studying innovative HIV medicines in the “real world” helps HCPs and patients make the best decisions for treatment and prevention
| Dr. Buzón discusses bridging science and reality, highlighting the vital role of real-world evidence in advancing HIV care ...
UNAIDS12d
U=U can help end HIV stigma and discrimination. Here’s how
U=U is short for Undetectable = Untransmittable. It means that when a person living with HIV, adheres to effective ...
Healio5d
HIV PrEP Curbside Consults: Black MSM Who Engages in High-Risk Behaviors
In this case-based Curbside Consult, Drs. Elion and Landovitz discuss how to select the most appropriate HIV pre-exposure prophylaxis (PrEP) option based on recent clinical evidence, access ...
147 HIV counsellors graduate as Health Ministry pilots ARV treatment drive, targeting 1.1m South Africans
The Gauteng Department of Health recently celebrated the graduation of 147 HIV testing services (HTS) counsellors at Accolades Boutique Hotel in Midrand, Johannesburg.